据医药魔方数据,2025前三季度中国License-out总金额共计920.3亿美元;信达与武田10月的交易金额最高可达114亿美元,中国创新药对外授权总金额当前已突破1000亿美元。此外,三生制药/辉瑞近期公告启动707两项全球三期临床,布局NSCLC和CRC。在今年5月,辉瑞以12.50亿美元预付款+48亿美元里程碑付款+双位数百分比的销售分成引进三生制药的PD-1/VEGF双抗。方正证券认为...
Source Link据医药魔方数据,2025前三季度中国License-out总金额共计920.3亿美元;信达与武田10月的交易金额最高可达114亿美元,中国创新药对外授权总金额当前已突破1000亿美元。此外,三生制药/辉瑞近期公告启动707两项全球三期临床,布局NSCLC和CRC。在今年5月,辉瑞以12.50亿美元预付款+48亿美元里程碑付款+双位数百分比的销售分成引进三生制药的PD-1/VEGF双抗。方正证券认为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.